Financial Snapshot

Revenue
$14.29K
TTM
Gross Margin
-73.54%
TTM
Net Earnings
-$374.5K
TTM
Current Assets
$93.72K
Q4 2019
Current Liabilities
$1.934M
Q4 2019
Current Ratio
4.85%
Q4 2019
Total Assets
$100.9K
Q4 2019
Total Liabilities
$1.934M
Q4 2019
Book Value
-$1.833M
Q4 2019
Cash
P/E
-3.472
Apr 17, 2023 EST
Free Cash Flow
-$339.3K
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $1.3 Million

About PREMIER BIOMEDICAL INC

Premier Biomedical, Inc. is a research-based company, which engages in the development and discovery of medical products. The company is headquartered in Whitefish, Montana. The company went IPO on 2012-02-23. The firm has developed a line of topical hemp oil pain relief products. The firm develops medical treatments for humans, specifically focusing on the treatment of Cancer Fibromyalgia, Traumatic Brain Injury (TBI), Alzheimer’s Disease (AD), Blood Sepsis and Viremia, Feldetrex. The firm offers eight pain relief products: 96-hour pain relief patch with 50 mg of hemp oil extract, 120 milligram (mg)/ 10 milliliter (ml) water-based roll-on applicator; 150 mg/ 30 ml oil-based pump spray applicator; 150 mg/ 2 oz. ointment; 200 mg/10 ml oil-based roll-on applicator; 500 mg/ 30 ml oil-based pump-spray applicator, and 500 mg/ 1 oz. ointment. The company offers extra-corporeal treatment of disease, PTSD treatment, anti-breast cancer drugs, hemp oil, anti-aging treatments and chemical and alcohol addiction treatment.

Industry: Biological Products, (No Diagnostic Substances) Peers: Actavia Life Sciences Inc GlobeStar Therapeutics Corp Entero Therapeutics Inc Endonovo Therapeutics Inc Innoveren Scientific Inc Q BioMed Inc.